ProMark® Risk Score

The ProMark® test is covered on a limited basis to assist selection of patients with early-stage, needle-biopsy–proven prostate cancer for conservative management (active surveillance) instead of definitive surgery or radiation. The policy states limited coverage but does not specify additional eligibility thresholds, documentation, or frequency limits.

"ProMark test is covered to help determine whether patients with early-stage, needle-biopsy–proven prostate cancer can be managed conservatively (active surveillance) rather than treated with defini..."

Sign up to see full coverage criteria, indications, and limitations.